Zydus Cadila's Virafin got emergency use approval for moderate COVID-19 cases by the Indian government on Saturday. Zydus Cadilla said in a statement that 10 million doses will be produced per month initially starting from June. 

Also Read: What is the price of Zydus Cadila's Virafin?

The pharma company's MD told Reuters that it aims at producing 240 million doses per year. Initially, the in-house capacity of production will be 120 million doses per year, which the company aims to expand. 

Virafin can be used when the COVID-19 patients have moderate or mild symptoms. The drug is said to reduce the viral load and helps in avoiding the need of oxygen. 

Also Read: Biden administration under pressure to dispatch AstraZeneca vaccines to India

When the dose will be administered in the early stage of COVID, it wll help the patients to recover faster and avoid severe complications. The drug will only be available on the prescription of medical specialists for use in hospitals. 

#ZydusCadila #India #CoronaVaccine #Vaccine #covid19 #Virafin